Sugi Predict

Sugi Predict / Compounds / SCHEMBL1793142

SCHEMBL1793142

SCHEMBL1793142

CCCCc1cccc(C(=O)OCC)c1

nearest known ligand 0.81

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 3/20 0.81
▸ CYP4A11 Q02928 3/20 0.81
▸ NPC1 O15118 3/20 0.56
▸ RAB9A P51151 3/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ CYP1A2 P05177 1/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ HPGD P15428 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ MEP1B Q16820 1/20 0.54
▸ MAPT P10636 2/20 0.53
▸ PPARG P37231 2/20 0.52
▸ PPARA Q07869 2/20 0.52
▸ CA2 P00918 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20178551 0.94 CYP4F2 (0.76) CYP4F2CYP4A11NPC1RAB9ASMN1; SMN2
SCHEMBL12035616 0.90 CYP4F2 (0.75) CYP4F2CYP4A11NPC1RAB9ASMN1; SMN2
SCHEMBL8799839 0.89 CYP4F2 (1.00) CYP4F2CYP4A11NPC1RAB9ASMN1; SMN2
SCHEMBL28280189 0.88 CYP4F2 (0.76) CYP4F2CYP4A11NPC1RAB9ASMN1; SMN2
SCHEMBL11587961 0.88 CYP4F2 (0.76) CYP4F2CYP4A11NPC1RAB9ASMN1; SMN2
SCHEMBL17563119 0.88 CYP4F2 (0.76) CYP4F2CYP4A11NPC1RAB9ASMN1; SMN2
SCHEMBL28399629 0.87 CYP4F2 (0.61) CYP4F2CYP4A11PPARGPPARA
SCHEMBL29233053 0.87 CYP4F2 (0.61) CYP4F2CYP4A11PPARGPPARA
SCHEMBL662273 0.87 CYP4F2 (0.74) CYP4F2CYP4A11NPC1RAB9ASMN1; SMN2
SCHEMBL8723505 0.87 CYP4F2 (0.74) CYP4F2CYP4A11NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 — — US disclosed
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-13 — — US disclosed
US-20230132715-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 — — US disclosed
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-10-27 — — US disclosed
EP-2249426-B1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY MITSUBISHI CHEM CORP (JP) 2019-07-10 — — EP disclosed
CN-105762402-A Nonaqueous electrolyte solution and nonaqueous electrolyte battery 三菱化学株式会社 2016-07-13 — — CN disclosed
CN-103078137-B Nonaqueous electrolyte solution and nonaqueous electrolyte battery MITSUBISHI CHEMICAL CORP. (JP) 2015-09-16 — — CN disclosed
US-9083058-B2 Nonaqueous electrolytic solution and nonaqueous-electrolyte battery MITSUBISHI CHEMICAL CORPORATION (JP) 2015-07-14 — — US disclosed
CN-104600360-A NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY MITSUBISHI CHEM CORP 2015-05-06 — — CN disclosed
US-8916298-B2 Nonaqueous electrolytic solution and nonaqueous-electrolyte battery MITSUBISHI CHEMICAL CORPORATION (JP) 2014-12-23 — — US disclosed
US-20140134481-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2014-05-15 — — US disclosed
CN-103078137-A Nonaqueous electrolyte solution and nonaqueous electrolyte battery MITSUBISHI CHEM CORP 2013-05-01 — — CN disclosed
US-20120308883-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2012-12-06 — — US disclosed
EP-2520570-A1 AMINOPYRIDINE COMPOUND Ube Industries, Ltd. (JP) 2012-11-07 — — EP disclosed
US-20120259123-A1 AMINOPYRIDINE COMPOUND UBE INDUSTRIES, LTD. (JP) 2012-10-11 — — US disclosed
CN-102666490-A Aminopyridine compound UBE INDUSTRIES 2012-09-12 — — CN disclosed
US-20120219854-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2012-08-30 — — US disclosed
US-20110123871-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY MITSUBISHI CHEMCIAL (JP) 2011-05-26 — — US disclosed
CN-101960662-A Nonaqueous electrolyte solution and nonaqueous electrolyte battery MITSUBISHI CHEM CORP 2011-01-26 — — CN disclosed
EP-2249426-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY Mitsubishi Chemical Corporation (JP) 2010-11-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230132715-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CYP4F2 4361/4885CYP4A11 2332/4885NPC1 3159/4885
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CYP4F2 4361/4885CYP4A11 2332/4885NPC1 3159/4885
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CYP4F2 4361/4885CYP4A11 2332/4885NPC1 3159/4885
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CYP4F2 4361/4885CYP4A11 2332/4885NPC1 3159/4885
US-20120259123-A1 AMINOPYRIDINE COMPOUND PTGIS, QDPR, PTGIR CYP4F2 2119/4885CYP4A11 764/4885NPC1 1597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.